Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Breast Neoplasms 108Carcinoma, Non-Small-Cell Lung 97Multiple Myeloma 81Prostatic Neoplasms 74Colorectal Neoplasms 60Neoplasms 58Leukemia, Myeloid, Acute 56Lymphoma 48Squamous Cell Carcinoma of Head and Neck 43Melanoma 40Lung Neoplasms 40Ovarian Neoplasms 38Neoplasm Metastasis 37Pancreatic Neoplasms 36Lymphoma, Non-Hodgkin 36Carcinoma, Hepatocellular 34Lymphoma, Large B-Cell, Diffuse 33Head and Neck Neoplasms 32Sarcoma 31Carcinoma, Renal Cell 31Urinary Bladder Neoplasms 30Precursor Cell Lymphoblastic Leukemia-Lymphoma 30Endometrial Neoplasms 29Leukemia, Lymphocytic, Chronic, B-Cell 28Hodgkin Disease 28Triple Negative Breast Neoplasms 27Myelodysplastic Syndromes 27Hematologic Neoplasms 26Recurrence 25Glioma 25

Interventions

Sodium Chloride 1Amiodarone 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Atrial Fibrillation × 30 days × Clear all
NCT06067438 2026-05-22

Amiodarone for the Prevention of Atrial Fibrillation After Minimally Invasive Esophagectomy in Patients With Esophageal Cancer

OHSU Knight Cancer Institute

Phase 2 Recruiting
90 enrolled
Gastrointestinal

Atrial Fibrillation, Esophageal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡